Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments.
Alanine transaminase
Blood pressure
Cardiac biomarkers
Creatinine
Echocardiography
Heart histology
Monocrotaline
Morphometric analysis of pulmonary arteries
Randomization
Right ventricular systolic pressure
Sample size
Journal
MethodsX
ISSN: 2215-0161
Titre abrégé: MethodsX
Pays: Netherlands
ID NLM: 101639829
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
11
2019
accepted:
12
12
2019
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
30
1
2020
Statut:
epublish
Résumé
The identification of new treatments for primary pulmonary arterial hypertension (PAH) is a critical unmet need since there is no a definitive cure for this disease yet. Due to the complexity of PAH, a wide set of methods are necessary to assess the response to a pharmacological intervention. Thus, a rigorous protocol is crucial when experimental studies are designed. In the present experimental protocol, a stepwise approach was followed in a monocrotaline-induced PAH model in the rat, moving from the dose finding study of treatment compounds to the recognition of the onset of disease manifestation, in order to identify when to start a curative treatment. A complete multidimensional evaluation of treatment effects represented the last step. The primary study endpoint was the change in right ventricular systolic pressure after 14 days of treatment; echocardiographic and biohumoral markers together with heart and pulmonary arterial morphometric parameters were considered as secondary efficacy and/or safety endpoints and for the evaluation of the biologic coherence in the different results.
Identifiants
pubmed: 31993338
doi: 10.1016/j.mex.2019.100771
pii: S2215-0161(19)30347-4
pii: 100771
pmc: PMC6974770
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100771Informations de copyright
© 2019 The Authors.
Déclaration de conflit d'intérêts
Marco Milioli, Fabrizio Facchinetti, Silvia Cantoni, Marcello Trevisani are employees of Chiesi Farmaceutici S.p.A. The other authors have no conflicts of interest to declare.
Références
Chest. 2012 Aug;142(2):448-456
pubmed: 22281797
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Clin Cancer Res. 2008 Nov 15;14(22):7284-91
pubmed: 19010844
J Cardiovasc Pharmacol. 1999 Sep;34(3):321-6
pubmed: 10470987
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Pharmacol Res. 2013 Jul;73:35-43
pubmed: 23644256
J Pulm Respir Med. 2014 Aug 4;4(4):null
pubmed: 25705569
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Circ Res. 2018 Mar 30;122(7):1021-1032
pubmed: 29599278
Circ Res. 2017 Jun 9;120(12):1916-1926
pubmed: 28373349
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30545975
Eur J Pharmacol. 2019 Dec 15;865:172777
pubmed: 31697933
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
J Pharmacol Toxicol Methods. 2016 Jan-Feb;77:58-65
pubmed: 26516096
J Card Fail. 2004 Oct;10(5):433-41
pubmed: 15470655
Chest. 2017 Dec;152(6):1117-1119
pubmed: 28642105
Cardiovasc Res. 2014 Oct 1;104(1):37-48
pubmed: 25139747
Circ Res. 2004 Feb 20;94(3):385-93
pubmed: 14670839
Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H364-71
pubmed: 12063310
Nat Rev Cardiol. 2011 Jun 21;8(8):443-55
pubmed: 21691314
Eur J Pharmacol. 2011 Sep 30;667(1-3):287-91
pubmed: 21641342